Literature DB >> 10217311

Inhibition by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of responses to nitric oxide-donors in rat pulmonary artery: influence of the mechanism of nitric oxide generation.

K L Homer1, S A Fiore, J C Wanstall.   

Abstract

ODQ, (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, an inhibitor of soluble guanylate cyclase) inhibits vasorelaxant responses to nitric oxide (NO)-donor drugs, but the extent of the inhibition varies depending on the NO donor studied. The purpose of this study was to test the hypothesis that these variations in the effects of ODQ reflect differences in the mechanisms whereby each NO donor generates NO. On pulmonary artery preparations pre-contracted submaximally with phenylephrine, ODQ (3 microM) almost abolished the relaxant responses to glyceryl trinitrate, isosorbide dinitrate and nitroprusside; each of these drugs requires activation in the tissue (by enzymes or reducing agents) to generate NO. In contrast, ODQ (3 microM) caused a parallel shift in the concentration-relaxation curves to linsidomine (SIN-1), FK409, MAHMA NONOate and spermine NONOate (1.63 to 2.54 log units) with no depression in maximum response; each of these NO donors generates NO in the physiological bathing solution without requiring tissue activation. For the four drugs in this group, the effects of 10 microM ODQ were not significantly greater than the effects of 3 microM ODQ; thus there was an ODQ-resistant component to the response suggesting that part of the response involved a mechanism that was independent of soluble guanylate cyclase. NO donors that require tissue activation probably generate NO within the smooth-muscle cell, whereas those that do not require tissue activation generate NO outside the cell. Hence it is concluded that the site of NO generation (intra- or extracellular) might determine whether or not there is an ODQ-resistant component in the relaxation response.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217311     DOI: 10.1211/0022357991772240

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

1.  Augmented dilation to nitric oxide in uterine arteries from rats with type 2 diabetes: implications for vascular adaptations to pregnancy.

Authors:  Styliani Goulopoulou; Johanna L Hannan; Takayuki Matsumoto; Adviye Ergul; R Clinton Webb
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-12-13       Impact factor: 4.733

2.  Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate.

Authors:  Kerry L Homer; Janet C Wanstall
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

3.  A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations.

Authors:  Michael S Crane; Adriano G Rossi; Ian L Megson
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

4.  Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.

Authors:  Edward A Pankey; Manish Bhartiya; Adeleke M Badejo; Umair Haider; Johannes-Peter Stasch; Subramanyam N Murthy; Bobby D Nossaman; Philip J Kadowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-07       Impact factor: 4.733

5.  Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion.

Authors:  J C Wanstall; T K Jeffery; A Gambino; F Lovren; C R Triggle
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

6.  Cyclic GMP-independent relaxation of rat pulmonary artery by spermine NONOate, a diazeniumdiolate nitric oxide donor.

Authors:  K L Homer; J C Wanstall
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

7.  S-nitrosocaptopril: in vitro characterization of pulmonary vascular effects in rats.

Authors:  Debbie Y Y Tsui; Agatha Gambino; Janet C Wanstall
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.